| Targeted metabolomics analysis of amino acids and acylcarnitines as risk markers for diabetes by LC–MS/MS technique BLFR Shaghayegh Hosseinkhani, Babak Arjmand, Arezou Dilmaghani-Marand, Sahar ... scientific reports, 2022 | 29 | 2022 |
| Mass spectrometry with derivatization method for concurrent measurement of amino acids and acylcarnitines in plasma of diabetic type 2 patients with diabetic nephropathy P Esmati, N Najjar, S Emamgholipour, S Hosseinkhani, B Arjmand, ... Journal of Diabetes & Metabolic Disorders 20, 591-599, 2021 | 16 | 2021 |
| Association of circulating omega 3, 6 and 9 fatty acids with gestational diabetes mellitus: a systematic review S Hosseinkhani, H Dehghanbanadaki, H Aazami, P Pasalar, M Asadi, ... BMC Endocrine Disorders 21 (1), 120, 2021 | 13 | 2021 |
| The trend in application of omics in type 2 diabetes researches; a bibliometric study S Hosseinkhani, H Aazami, E Hashemi, H Dehghanbanadaki, ... Diabetes & Metabolic Syndrome: Clinical Research & Reviews 15 (5), 102250, 2021 | 10 | 2021 |
| Association of plasma acylcarnitines and amino acids with hypertension: A nationwide metabolomics study B Arjmand, H Dehghanbanadaki, M Yoosefi, N Rezaei, ... PloS One 18 (1), e0279835, 2023 | 7 | 2023 |
| Effect of rosiglitazone on circulating malondialdehyde (MDA) level in diabetes based on a systematic review and meta-analysis of eight clinical trials Z Majidi, S Hosseinkhani, N Amiri-Dashatan, S Emamgholipour, ... Journal of investigative medicine 69 (3), 697-703, 2021 | 6 | 2021 |
| The association between acylcarnitine and amino acids profile and metabolic syndrome and its components in Iranian adults: Data from STEPs 2016 H Taghizadeh, S Emamgholipour, S Hosseinkhani, B Arjmand, N Rezaei, ... Frontiers in Endocrinology 14, 1058952, 2023 | 5 | 2023 |
| Omics experiments in Iran, a review in endocrine and metabolism disorders studies S Hosseinkhani, B Arjmand, F Bandarian, H Aazami, N Hadizadeh, ... Journal of Diabetes & Metabolic Disorders, 1-6, 2021 | 5 | 2021 |
| Evaluating the association between amino acid and acylcarnitine profiles and different levels of coronary artery disease risk in postmenopausal women using targeted … S Hosseinkhani, S Emamgholipour, P Salari, K Khalagi, S Shirani, ... Menopause 29 (9), 1062-1070, 2022 | 4 | 2022 |
| Bibliometric overview of Ramadan fasting studies during 2010–2021 H Dehghanbanadaki, H Aazami, S Hosseinkhani, F Razi, F Bandarian, ... Diabetes & Metabolic Syndrome: Clinical Research & Reviews 16 (7), 102531, 2022 | 4 | 2022 |
| Metabolomics signature of cardiovascular disease in patients with diabetes, a narrative review S Dodangeh, H Taghizadeh, S Hosseinkhani, P Khashayar, P Pasalar, ... Journal of Diabetes & Metabolic Disorders 22 (2), 985-994, 2023 | 2 | 2023 |
| Metabolomics profile and 10-year atherosclerotic cardiovascular disease (ASCVD) risk score H Dehghanbanadaki, S Dodangeh, P Parhizkar Roudsari, ... Frontiers in Cardiovascular Medicine 10, 1161761, 2023 | 2 | 2023 |
| Circulating amino acids and acylcarnitines correlated with different CAC score ranges in diabetic postmenopausal women using LC–MS/MS based metabolomics approach S Hosseinkhani, P Salari, F Bandarian, M Asadi, S Shirani, N Najjar, ... BMC Endocrine Disorders 22 (1), 186, 2022 | 2 | 2022 |
| Association between ELMO1 gene polymorphisms and diabetic kidney disease: A systematic review and meta-analysis A Azarboo, S Hosseinkhani, A Ghaseminejad-Raeini, H Aazami, ... Plos one 19 (1), e0295607, 2024 | 1 | 2024 |
| Knowledge gaps in diabetes research: an evidence mapping of the literature S Esmaeili, F Bandarian, F Gharishvandi, F Razi, S Hosseinkhani, ... Journal of Diabetes & Metabolic Disorders 21 (1), 1139-1148, 2022 | 1 | 2022 |
| Plasma acylcarnitines and amino acids in dyslipidemia: An integrated metabolomics and machine learning approach A Etemadi, F Hassanzadehkiabi, M Mirabolghasemi, M Ahmadi, ... Journal of Diabetes & Metabolic Disorders, 1-13, 2024 | | 2024 |
| Insight into the Predictive Power of Surrogate Diagnostic Indices for Identifying Individuals with Metabolic Syndrome. S Hosseinkhani, K Forouzanfar, N Hadizadeh, F Razi, S Darzi, ... Endocrine, Metabolic & Immune Disorders Drug Targets, 2024 | | 2024 |
